Zim Laboratories (NSE:ZIMLAB) Altman Z2-Score: 3.64 (As of Jun. 26, 2026) — Near Median


NSE:ZIMLAB Zim Laboratories Ltd NSE:ZIMLAB
76 GF Score
Price ₹124.90
GF Value ₹102.87
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Zim Laboratories Altman Z2-Score?

Zim Laboratories NSE:ZIMLAB -2.32% 76 Altman Z2-Score is 3.64 as of Jun. 26, 2026, which is at its 10-year median of 3.64. GuruFocus rates NSE:ZIMLAB with a GF Score™ of 76/100 and a GF Value™ of ₹102.87 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 997 Drug Manufacturers companies, Zim Laboratories ranks worse than 52.16% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

Zim Laboratories has a Altman Z2-Score of 3.64, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Zim Laboratories's Altman Z2-Score or its related term are showing as below:

NSE:ZIMLAB' s Altman Z2-Score Range Over the Past 10 Years
Min: 2.91   Med: 3.64   Max: 5.16
Current: 3.64

During the past 12 years, Zim Laboratories's highest Altman Z2-Score was 5.16. The lowest was 2.91. And the median was 3.64.


Zim Laboratories  (NSE:ZIMLAB) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Zim Laboratories Altman Z2-Score Related Terms


Zim Laboratories Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Zim Laboratories's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zim Laboratories Altman Z2-Score Chart

Zim Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.05 5.16 3.80 3.69 3.64

Zim Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.69 0.00 2.47 0.00 3.64

NSE:ZIMLAB vs ZTS: Altman Z2-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Zim Laboratories's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zim Laboratories Altman Z2-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zim Laboratories's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Zim Laboratories's Altman Z2-Score falls into.


NSE:ZIMLAB
76GF Score
Zim Laboratories Ltd NSE:ZIMLAB
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zim Laboratories Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Zim Laboratories's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.1584+3.26*0.3241+6.72*0.0397+1.05*1.2176
=3.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2026:
Total Assets was ₹5,394 Mil.
Total Current Assets was ₹2,758 Mil.
Total Current Liabilities was ₹1,904 Mil.
Retained Earnings was ₹1,748 Mil.
Pre-Tax Income was 49.417 + 60.468 + -3.438 + -24.32 = ₹82 Mil.
Interest Expense was -33.103 + -34.291 + -31.594 + -33.035 = ₹-132 Mil.
Total Liabilities was ₹2,432 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(2758.085 - 1903.924)/5393.871
=0.1584

X2=Retained Earnings/Total Assets
=1747.982/5393.871
=0.3241

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(82.127 - -132.023)/5393.871
=0.0397

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(2961.536 - 0)/2432.33
=1.2176

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Zim Laboratories has a Altman Z2-Score of 3.64 indicating it is in Safe Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 3.64 mean?
Zim Laboratories (NSE:ZIMLAB) has a Altman Z2-Score of 3.64 as of Jun. 26, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Zim Laboratories and its competitors. This is near median its historical median of 3.64. Over the past decade, Zim Laboratories' Altman Z2-Score has ranged from 2.91 to 5.16. According to the industry distribution chart, Zim Laboratories ranks #520 out of 997 companies in the Drug Manufacturers industry, placing it in the top 52.2%.
Is Zim Laboratories' Altman Z2-Score too high?
Zim Laboratories' current Altman Z2-Score of 3.64 is near median its 10-year median of 3.64. Over the past 10 years, this metric has ranged from a low of 2.91 to a high of 5.16. The Drug Manufacturers industry median Altman Z2-Score is 3.87. Zim Laboratories' value of 3.64 is 5.9% below this industry median. Based on the distribution chart, Zim Laboratories ranks #520 out of 997 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Zim Laboratories has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zim Laboratories' Altman Z2-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zim Laboratories ranks #520 out of 997 companies for Altman Z2-Score. This places Zim Laboratories in the lower half of its industry. The industry median Altman Z2-Score is 3.87. Zim Laboratories' value of 3.64 is 5.9% below this benchmark. Historically, Zim Laboratories' own Altman Z2-Score has ranged from 2.91 to 5.16 over the past decade. While the company's 10-year median is 3.64 vs. the industry median of 3.87, Zim Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Drug Manufacturers company?
The median Altman Z2-Score among Drug Manufacturers companies is 3.87, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zim Laboratories's current Altman Z2-Score of 3.64 is 5.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Zim Laboratories and its competitors. For the Drug Manufacturers industry, the median Altman Z2-Score is 3.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zim Laboratories's current Altman Z2-Score is 3.64, which is near median its own 10-year median of 3.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zim Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Zim Laboratories (NSE:ZIMLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹102.87, compared to a current price of ₹124.90 — trading 21.4% above its estimated fair value. The current Altman Z2-Score is 3.64, which is near median its 10-year median of 3.64 and 5.9% below the Drug Manufacturers industry median of 3.87. Zim Laboratories' overall GF Score™ is 76/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Zim Laboratories (NSE:ZIMLAB), the current Altman Z2-Score is 3.64 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zim Laboratories (NSE:ZIMLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Zim Laboratories stock appears to be overvalued. The current stock price of ₹124.90 is trading 21.4% above its estimated GF Value™ of ₹102.87. GuruFocus considers Zim Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:ZIMLAB:

  • Altman Z2-Score: 3.64 (near median its 10-year median of 3.64)
  • GF Value™: ₹102.87 vs. price of ₹124.90 (21.4% above fair value)
  • GF Score™: 76/100 with 8 warning signs
  • Industry Position: 5.9% below the Drug Manufacturers median (#520 of 997)

No single metric tells the full story. See the NSE:ZIMLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zim Laboratories Business Description

Other Exchanges 541400:India
Address Nelson Square, Chhindwara Road, Sadoday Gyan, Ground Floor, Opposite NADT, Nagpur, MH, IND, 440 013
Zim Laboratories Ltd is engaged in the manufacturing of formulation drugs and pre formulation ingredients in India and marketing and selling these within and outside India. It is engaged in manufacturing &wholesale of pharmaceutical products, market research and research & development activities. The Group is mainly engaged in the business of pharmaceuticals. It has presence in India and Outside India. The company generates majority of revenue from India. Its products are Oral Thin Films, Pre-formulations Intermediates, Finished Formulations.
76GF Score

Get the complete analysis for NSE:ZIMLAB

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹124.90
Price
₹102.87
GF Value